Dolasetron

Generic Name
Dolasetron
Brand Names
Anzemet
Drug Type
Small Molecule
Chemical Formula
C19H20N2O3
CAS Number
115956-12-2
Unique Ingredient Identifier
82WI2L7Q6E
Background

Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is not shown to have activity at other known ...

Indication

For the prevention of nausea and vomiting associated with emetogenic cancer chemotherapy, including initial and repeat courses of chemotherapy. Also used for the prevention of postoperative nausea and vomiting. This drug can be used intravenously for the treatment of postoperative nausea and vomiting.

Associated Conditions
Chemotherapy-Induced Nausea and Vomiting, Post Operative Nausea and Vomiting (PONV)
Associated Therapies
-
Clinical Trials
Related News

Evaluating the Efficacy and Safety of HSK21542 Injection in Chemotherapy-induced Nausea and Vomiting

Phase 2
Not yet recruiting
Conditions
Nausea and Vomiting, Chemotherapy-Induced
Interventions
Drug: HSK21542
Drug: Dolasetron
First Posted Date
2024-09-13
Last Posted Date
2024-09-19
Lead Sponsor
First Affiliated Hospital of Wenzhou Medical University
Target Recruit Count
180
Registration Number
NCT06593782

Efficacy of Dolasetron in Patients With Fibromyalgia

Phase 3
Completed
Conditions
Fibromyalgia
Interventions
Drug: Placebo
Drug: Dolasetron
First Posted Date
2009-01-12
Last Posted Date
2009-01-12
Lead Sponsor
University Hospital, Limoges
Target Recruit Count
60
Registration Number
NCT00820326
Locations
🇫🇷

Service de Rhumatologie, CHu de Limoges, Limoges, France

The Pharmacokinetic Interaction Between Oral Casopitant and Oral Dolasetron, Granisetron or Rosiglitazone in Subjects

First Posted Date
2007-08-06
Last Posted Date
2017-08-03
Lead Sponsor
GlaxoSmithKline
Target Recruit Count
16
Registration Number
NCT00511823
Locations
🇺🇸

GSK Investigational Site, Evansville, Indiana, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy